Vancouver, British Columbia – TheNewswire – October 1, 2020 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (the “Corporation” or “Blackhawk“), is pleased to provide the following corporate updates on the status of the COVID-19 Testing Kits, NuWave Foods and Sac Pharma.

The preparation of the Health Canada application has commenced. The manufacturer is submitting both the ExProbe SARS-CoV-2 Testing Kit and a SARS-CoV-2 IgG/IgM Rapid Test Kit applications for medical devices under the Interim Order (IO) issued by Health Canada for use in relation to COVID-19. Following submission of the application, Health Canada timelines will vary on a case by case basis for an IO application review depending on the extent of information requests received. Blackhawk makes no representations and cannot provide any guarantees on Health Canada review timelines, or that approval will utlmately be granted.

Sales and distribution of the test kits have continued outside of Canada in the meantime, with a first nations group in California recently purchasing a significant sample size of the SARS-CoV-2 IgG/IgM Rapid Test Kit. The intent is to provide them with the ability to establish a PCR testing facility once they are ready. Blackhawk sales teams have continued negotiations with other groups and looks forward to sharing the results of those conversations in the near future.

The NuWave team is preparing for the launch of its “Forever Brands” products and completing negotiations on new equipment and its exclusivity on products. Samples are being produced this week as well as packaging and logos. We will be updating the market and our website as media becomes available.

Our newest investment, Sac Pharma, continues to grow. Sales across cannabis retailers in California have been strong in the wake of the COVID-19 pandemic. With increases of about 30% across the board, demand has remained strong despite the mass shuttering of traditional retail shopping. Typically, wholesale cannabis prices dip in the fall, due to large scale annual harvests from greenhouse and outdoor producers. The California wildfires, however, have affected a substantial number of large-scale production areas, delaying, or in many cases eliminating products that would otherwise be coming to market. Steadily increasing demand with reduced supply has left those whose production remains unaffected in a strong position to deliver these highly coveted products to market.

Sac Pharma is a tenured operator with well-established channels of distribution. As such, it will be able to continue delivery of its core products to customers amidst the pandemic. Sac Pharma has implemented safeguards to its operational procedures to ensure the continued safety of its product and employees.

Sac Pharma completed planned infrastructure upgrades to the CO2 delivery system in its facility in Q2 and Q3 of 2020, paving the way for strong revenues amidst the pandemic. The company currently has several large harvests in process, with several more on schedule to close out the year. In addition to realizing the production benefit from its new and improved facility, the current market conditions have resulted in Sac Pharma pre-selling the entirety of its 2020 production.

“We are thankful the Sac Pharma team has remained safe during the pandemic” said Corey Travis, Founder of Sac Pharma. “Our hearts go out to those who have been affected by the California wildfires during this difficult time. We are encouraged by strong interest in our product lines and look forward to safely continuing to keep pace with demand during these unprecedented times.”

“We are working tirelessly on all our initiatives” said Frederick Pels, CEO of Blackhawk. “The IO application is very detailed and we are excited for its submission. In the interim, we will be presenting our Test Kit suite for contingent sales in Canada and continuing our efforts in other markets relentlessly. As Sac Pharma and NuWave continue to grow, I hope to bring substantially value to our shareholders and I look forward to updating our investors as soon as possible.”

For further information please contact:

Frederick Pels, Chief Executive Officer


This email address is being protected from spambots. You need JavaScript enabled to view it.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Corporation within the meaning of applicable securities laws, including with respect to the approval of the Test Kits by Health Canada, and the marketing and distribution of the Test Kits in North and South America. The Corporation provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Corporation’s public filings under the Corporation’s SEDAR profile at Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.